Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03193463 | Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy | withdrawn | Early Phase 1 | 0 | Michael Vogelbaum, MD, PhDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | withdrawn | — | 0 | Duke UniversityOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | PIQUR Therapeutics AGINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02986919 | Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT01453465 | Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor | withdrawn | — | 0 | Children's Oncology GroupNETWORK | 1 | Aug 7, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT02014545 | Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 31, 2018 | clinicaltrials |
| NCT01740570 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT01736722 | MRI-Guided LITT for Treatment Metastatic Brain Tumors | withdrawn | N/A | 0 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02977689 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT00944580 | A Vaccine Study for High Risk Cancers | withdrawn | Phase 1 | 0 | Penn State UniversityOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02987010 | Phase 2 Study of IDH305 in Low Grade Gliomas | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Oct 11, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT00109798 | Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma | withdrawn | N/A | 0 | The Methodist Hospital Research InstituteOTHER | 0 | Sep 19, 2017 | clinicaltrials |
| NCT02745756 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Aug 30, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01260103 | Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | withdrawn | Phase 3 | 0 | Burzynski Research InstituteOTHER | 0 | Jul 26, 2017 | clinicaltrials |
| NCT01130623 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01182883 | A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01236586 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA(GINAKIT) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02735798 | 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets | withdrawn | Early Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 4, 2017 | clinicaltrials |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors | withdrawn | N/A | 0 | Sue O'DorisioOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00555984 | Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors(TIVA) | withdrawn | N/A | 0 | The Cleveland ClinicOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00980551 | Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma(RELRB1) | withdrawn | N/A | 0 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02976441 | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas | withdrawn | Early Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT01567787 | Proton Radiation Therapy for Spinal Tumors(NF01) | withdrawn | N/A | 0 | University of FloridaOTHER | 0 | Feb 10, 2017 | clinicaltrials |
| NCT01052363 | OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | West Virginia UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02165995 | Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 29, 2016 | clinicaltrials |
| NCT02655432 | Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population(POPH) | withdrawn | — | 0 | Université de MontréalOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01961934 | C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression | withdrawn | Phase 2 / Phase 3 | 0 | Phoenix Molecular ImagingOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | withdrawn | Phase 3 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02241668 | Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 26, 2016 | clinicaltrials |
| NCT00703859 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2019source: clinicaltrials